FDA-Approved Medications for Bipolar Disorder
Below is a comprehensive table of all FDA-approved medications for bipolar disorder, organized by indication, with key specifications for clinical use. 1, 2
Table: FDA-Approved Bipolar Disorder Medications
| Medication | FDA Approval | Acute Mania | Bipolar Depression | Maintenance | Age Restriction | Key Monitoring |
|---|---|---|---|---|---|---|
| Lithium | ✓ | ✓ | — | ✓ | ≥12 years | Serum levels (0.6-1.2 mEq/L), renal function (creatinine, eGFR), thyroid (TSH, T4), calcium, ECG baseline [1,3] |
| Valproate/Divalproex | ✓ | ✓ | — | — | Adults only | Liver function tests, CBC with platelets, ammonia if encephalopathy, serum levels (50-125 mcg/mL) [1,3] |
| Carbamazepine | ✓ | ✓ | — | ✓ | Adults only | CBC (risk of aplastic anemia/agranulocytosis), liver function, sodium, serum levels (4-12 mcg/mL), HLA-B*1502 in Asian ancestry [4] |
| Lamotrigine | ✓ | — | — | ✓ | Adults only | Skin monitoring (Stevens-Johnson syndrome risk, especially first 8 weeks), no routine labs required [1,2] |
| Aripiprazole | ✓ | ✓ | — | ✓ | ≥10 years (mania) | Weight, glucose, lipids, blood pressure, movement disorders (akathisia common) [1,2,3] |
| Aripiprazole LAI | ✓ | — | — | ✓ | Adults only | Same as oral aripiprazole, injection site reactions [2] |
| Asenapine | ✓ | ✓ | — | ✓ | ≥10 years (mania) | Weight, glucose, lipids, blood pressure, oral hypoesthesia (sublingual formulation) [2,3] |
| Cariprazine | ✓ | ✓ | ✓ | — | Adults only | Weight, glucose, lipids, blood pressure, movement disorders (akathisia) [2] |
| Lumateperone | ✓ | — | ✓ | — | Adults only | Weight, glucose, lipids, blood pressure [2] |
| Lurasidone | ✓ | — | ✓ | — | ≥10 years (depression) | Weight, glucose, lipids, blood pressure, akathisia, take with food (≥350 calories) [2,5,6] |
| Olanzapine | ✓ | ✓ | — | ✓ | ≥13 years (mania) | Weight (significant gain risk), glucose, lipids, blood pressure, prolactin [1,2,3] |
| Olanzapine + Fluoxetine | ✓ | — | ✓ | — | ≥10 years | Same as olanzapine plus serotonin syndrome monitoring [1,5,6] |
| Paliperidone | ✓ | ✓ | — | — | Adults only | Weight, glucose, lipids, blood pressure, prolactin, movement disorders, QTc prolongation [2,3] |
| Quetiapine | ✓ | ✓ | ✓ | ✓ | ≥10 years (mania) | Weight (significant gain risk), glucose, lipids, blood pressure, sedation, cataracts (baseline eye exam) [1,2,5,3] |
| Risperidone | ✓ | ✓ | — | — | ≥10 years (mania) | Weight, glucose, lipids, blood pressure, prolactin (significant elevation), movement disorders [1,2,3] |
| Risperidone LAI | ✓ | — | — | ✓ | Adults only | Same as oral risperidone, injection site reactions [2] |
| Ziprasidone | ✓ | ✓ | — | — | Adults only | QTc prolongation (baseline and follow-up ECG), electrolytes (K+, Mg2+), take with food (≥500 calories) [1,7,3] |
| Chlorpromazine | ✓ | ✓ | — | — | Adults only | Movement disorders, blood pressure (orthostasis), anticholinergic effects, rarely used first-line [1] |
Critical Clinical Specifications
Acute Mania Treatment
- First-line options: Lithium, valproate, aripiprazole, asenapine, cariprazine, olanzapine, quetiapine, risperidone 1, 2
- Pediatric-approved (≥10-13 years): Aripiprazole, asenapine, olanzapine, quetiapine, risperidone 1, 2
Bipolar Depression Treatment
- FDA-approved options: Cariprazine, lumateperone, lurasidone, olanzapine-fluoxetine, quetiapine 2, 5, 6
- Pediatric-approved: Lurasidone (≥10 years), olanzapine-fluoxetine (≥10 years) 2
- Critical caveat: Antidepressant monotherapy (without mood stabilizer) can precipitate mania and is NOT FDA-approved 1
Maintenance Treatment
- FDA-approved: Aripiprazole (including LAI), asenapine, carbamazepine, lamotrigine, lithium, olanzapine, quetiapine, risperidone LAI 1, 2
- Duration: Minimum 2 years after last episode, often lifelong 4
Monitoring Frequency 3
- Baseline: All metabolic parameters (weight, glucose, lipids), renal/hepatic function, CBC, ECG (for specific agents)
- Follow-up:
- Weight: Monthly for first 3 months, then quarterly
- Glucose/lipids: 3 months, then annually (more frequently with olanzapine/quetiapine)
- Lithium levels: Weekly until stable, then every 3-6 months
- Thyroid/renal (lithium): Every 6-12 months
Common Pitfalls to Avoid
Lithium requires close monitoring - Cannot be initiated without laboratory monitoring capabilities; therapeutic window is narrow (0.6-1.2 mEq/L) 4, 1
Metabolic syndrome risk - Olanzapine and quetiapine carry highest risk for weight gain and metabolic disruption; lurasidone is metabolically neutral 2, 5, 6
Lamotrigine rash - Titrate slowly (25 mg/day for 2 weeks, then 50 mg/day for 2 weeks); faster titration or concurrent valproate increases Stevens-Johnson syndrome risk 1
QTc prolongation - Ziprasidone requires ECG monitoring; avoid with other QTc-prolonging drugs or electrolyte abnormalities 7, 3
Food requirements - Lurasidone requires ≥350 calories, ziprasidone requires ≥500 calories for adequate absorption 5, 3
Pregnancy considerations - Valproate has highest teratogenicity risk (neural tube defects, cognitive impairment); avoid in women of childbearing potential when possible 3